Get the Stockscreener App
4.44
0.89%
-0.04
Foghorn Therapeutics Inc stock is traded at $4.44, with a volume of 89,994.
It is down -0.89% in the last 24 hours and down -1.99% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.48
Open:
$4.53
24h Volume:
89,994
Relative Volume:
0.44
Market Cap:
$251.09M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-1.8974
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+1.83%
1M Performance:
-1.99%
6M Performance:
-2.20%
1Y Performance:
-23.18%
1-Day Range:
$4.4301
$4.545
1-Week Range:
$4.33
$4.63
52-Week Range:
$2.9448
$6.7899
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.44 | 253.35M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - TipRanks
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer By Investing.com - Investing.com Nigeria
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer - Investing.com
Why Foghorn Therapeutics Inc. stock remains on buy listsJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target By Investing.com - Investing.com South Africa
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target - Investing.com
R/R Acute Myeloid Leukemia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi - Barchart.com
Published on: 2025-12-02 00:54:46 - Newser
Volatility Watch: Will Foghorn Therapeutics Inc stock deliver better than expected guidanceBond Market & Verified Momentum Stock Ideas - BỘ NỘI VỤ
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Recommendation of “Buy” from Analysts - Defense World
What analysts say about Foghorn Therapeutics Inc stockMarket Sentiment Extremes & Maximum Profit Growth - earlytimes.in
Foghorn Therapeutics (NASDAQ:FHTX) Upgraded at Wall Street Zen - MarketBeat
Foghorn Therapeutics CEO joins Evercore Healthcare Conference - Traders Union
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference - The Manila Times
Foghorn Therapeutics (Nasdaq: FHTX) to Join 8th Evercore Healthcare Conference - Stock Titan
Why Foghorn Therapeutics Inc. stock is a must watch in 2025Quarterly Performance Summary & Fast Moving Market Watchlists - newser.com
Can Foghorn Therapeutics Inc. stock maintain growth trajectory2025 Performance Recap & Risk Controlled Daily Plans - newser.com
How Foghorn Therapeutics Inc. stock reacts to Fed rate cutsJuly 2025 Momentum & Weekly Market Pulse Alerts - newser.com
How Foghorn Therapeutics Inc. stock valuations compare to rivalsQuarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Is Foghorn Therapeutics Inc. stock safe for conservative investorsQuarterly Portfolio Report & Verified Momentum Watchlists - newser.com
Is Foghorn Therapeutics Inc. stock bottoming outShare Buyback & Fast Gain Stock Tips - newser.com
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? - Zacks Investment Research
FHTX: SMARCA2 program advances with Lilly partnership; multiple novel assets near IND and strong funding - TradingView
Identifying reversal signals in Foghorn Therapeutics Inc.July 2025 Action & AI Enhanced Trading Signals - newser.com
How Foghorn Therapeutics Inc. stock compares to growth peers2025 Top Gainers & Smart Investment Allocation Tips - newser.com
Check Out Foghorn Therapeutics Inc (FHTX)’s Trade Data Rather Than the Analysts’ Views - Setenews
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):